On interaction of activated protein C with human aortic smooth muscle cells attenuating the secretory group IIA phospholipase A2 expression

Thrombosis Research

Volumn 122, Issue 1, 2008, Pages 69-76

  Menschikowski, Mario ^a   Hagelgans, Albert ^a   Hempel, Ute ^b   Lattke, Peter ^a   Ismailov, Iskander ^c   Siegert, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Activated protein C; Endothelial protein C receptor; Protease activated receptors; Secretory phospholipase A2

Indexed keywords

ACTIVATED PROTEIN C; CCAAT ENHANCER BINDING PROTEIN BETA; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE A2;

ARTICLE; DNA BINDING; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER;

AORTA; BINDING SITES; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; KINETICS; MUSCLE, SMOOTH, VASCULAR; PHOSPHOLIPASES A2, SECRETORY; PROTEIN C; RNA, MESSENGER;

EID: 42649135164     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.08.015     Document Type: Article

References (34)

1. 2 superfamily of signal transduction enzymes. Trends Biochem Sci 22 (1997) 1-2
2. 2. J Biol Chem 273 (1998) 14411-14423
3. 2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat 79 (2006) 1-33
4. 2 involves binding to factor Xa. J Biol Chem 273 (1998) 23764-23772
5. 2 - a mediator between proximal and distal effectors of inflammation. Immunol Today 12 (1991) 143-146
6. Waydhas C., Nast-Kolb D., Duswald K.H., Lehnert P., and Schweiberer L. Prognostic value of serum phospholipase A in the multitraumatized patient. Klin Wochenschr 67 (1989) 203-206
7. 2. Annu Rev Pharmacol Toxicol 39 (1999) 175-189
8. 2 group IIA. Curr Med Chem 12 (2005) 3011-3026
9. 2, in the treatment of rheumatoid arthritis. J Rheumatol 32 (2005) 417-423
10. 2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 1761 (2006) 1373-1382
11. Dahlback B., and Villoutreix B.O. The anticoagulant protein C pathway. FEBS Lett 579 (2005) 3310-3316
12. Grinnell B.W., and Joyce D. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29 (2001) S53-S60
13. Mann H.J. Recombinant human activated protein C in severe sepsis. Am J Health Syst Pharm 59 (2002) S19-S23
14. Macias W.L., Yan S.B., Williams M.D., Um S.L., Sandusky G.E., Ballard D.W., et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 9 (2005) S38-S45
15. Joyce D.E., Gelbert L., Ciaccia A., DeHoff B., and Grinnell BW. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276 (2001) 11199-11203
16. Yuksel M., Okajima K., Uchiba M., Horiuchi S., and Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. Thromb Haemost 88 (2002) 267-273
17. Brueckmann M., Hoffmann U., Dvortsak E., Lang S., Kaden J.J., Borggrefe M., et al. Drotrecogin alfa (activated) inhibits NF-κB activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 53 (2004) 528-533
18. 2. Biochim Biophys Acta 1488 (2000) 149-158
19. 2 in rat renal mesangial cells. FEBS Lett 364 (1995) 218-222
20. 2 gene by cAMP and interleukin-1β in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-κB and Ets transcription factors. Biochem J 368 (2002) 415-424
21. 2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim Biophys Acta 1733 (2005) 157-171
22. Sturn D.H., Kaneider N.C., Feistritzer C., Djanani A., Fukudome K., and Wiedermann C.J. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102 (2003) 1499-1505
23. Versteeg H.H., Nijhuis E., van den Brink G.R., Evertzen M., Pynaert G.N., van Deventer S.J., et al. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 350 (2000) 717-722
24. Axmann A., Seidel D., Reimann T., Hempel U., and Wenzel K.W. Transforming growth factor-β1-induced activation of the Raf-MEK-MAPK signaling pathway in rat lung fibroblasts via a PKC-dependent mechanism. Biochem Biophys Res Commun 249 (1998) 456-460
25. 2-type IIA by protein kinase C in rat renal mesangial cells. Biochem Pharmacol 58 (1999) 1751-1758
26. Uchiba M., Okajima K., Oike Y., Ito Y., Fukudome K., Isobe H., et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 95 (2004) 34-41
27. Xue M., Campbell D., Sambrook P.N., Fukudome K., and Jackson C.J. Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. J Invest Dermatol 125 (2005) 1279-1285
28. Bretschneider E., Uzonyi B., Weber A.A., Fischer J.W., Pape R., Lotzer K., et al. Human vascular smooth muscle cells express functionally active endothelial cell protein C receptor. Circ Res 100 (2007) 255-262
29. Riewald M., Petrovan R.J., Donner A., Mueller B.M., and Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296 (2002) 1880-1882
30. Bretschneider E., Kaufmann R., Braun M., Nowak G., Glusa E., and Schror K. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol 132 (2001) 1441-1446
31. 2 specific inhibitor, in rat carrageenan-induced pleurisy. Inflammation 17 (1993) 107-119
32. 2. Am J Pathol 134 (1989) 807-811
33. 2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 33 (2005) 1741-1748
34. 2. J Biol Chem 277 (2002) 5849-5857